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ABSTRACT
Context: Parkinson’s disease (PD) is a neurodegenerative disorder due to gradual loss of dopaminergic
nerves in the substantia nigra (SN) in the midbrain. PD leads to certain motor disorders including resting
tremor, muscle stiffness and slow movement. Medicinal plants have shown positive pharmacological
effects in treating different models of PD.
Objective: Tendency to use natural products, especially plants, for the treatment of PD has been grow-
ing. This article reviews the basic aspects of medicinal plants and their bioactive compounds that could
be used to treat PD.
Methods: Reliable articles indexed in databases ISI, SID, PubMed, PubMed Central, Scopus and Web of
Science were used. A total of 12 plant-derived active ingredients and 18 herbal extracts were included.
Different compounds have so far been isolated from plants that affect PD especially by targeting path-
ways associated with the pathogenesis of the disease.
Results: Although some herbal extracts such as Hibiscus asper Hook. f. (Malvaceae), Ginkgo biloba L.
(Ginkgoaceae), Carthamus tinctorius L (Asteraceae) and certain active ingredients, such as berberine and
curcumin, have shown positive effects in animal models of PD, potential active ingredients and mecha-
nisms of action should be investigated in additional studies.
Discussion and conclusions: Despite the wide variety of plants in the world, a limited number of them
have been studied for anti-Parkinsonian activity, and therefore, there are numerous perspectives in this
field for future studies on plants and their bioactive compounds.
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Introduction
Parkinson’s disease (PD) was first described by James Parkinson
in 1817. The prevalence of PD is about 1% in people aged over
65 years. It begins between the ages of 40 and 70 and is very
rare under the age of 20. If PD begins under the age of 20 years,
it is referred to as young onset PD, which has a different path-
ology than other types of PD, is usually inherited, and is due to
Wilson’s disease or Huntington’s disease. PD is more prevalent
in men than in women by a ratio of 3:2 (Postuma et al. 2015).
The prevalence of PD is nearly 160 people per 100,000 popu-
lation and its incidence is about 20 people per 100,000 popula-
tion. The prevalence and incidence of the disease increase with
age, so that at the age of 70 years, the prevalence is nearly 550
people per 100,000 and the incidence is 120 people per 100,000.
Factors such as trauma, overwork, exposure to coldness, inflex-
ible personality and stress are considered to be the predisposing
factors; however, this has not yet been definitively proven
(Tysnes and Storstein 2017).
Etiology
The aetiology of PD is unknown. The disease, however, seems to
be due to the dopamine depletion in the nigrostriatal pathway.
Typically, intra-cytoplasmic inclusions, called Lewy bodies of
dopamine neurons, are detected in PD. The degeneration of
dopaminergic neurons in the substantia nigra (SN) compacta,
followed by impaired release of dopamine in striatum, is a major
cause of the disease; however, genetic factors have also been
shown to be effective in the development of this disease. In 23%
of cases, no genetic factor is identified. Several hypotheses have
been raised for the death of dopaminergic cells in the SN com-
pacta, such as mitochondrial complex defect associated with the
electron transport chain, iron accumulation, protein accumula-
tion, inflammatory immune responses along with environmental
factors such as physical trauma and infection, liver cytochrome
p450 dysfunction and increased formation of free radicals (Wang
et al. 2015).
Pathogenesis
PD is a neurodegenerative and progressive disease that is associ-
ated with various motor and debilitating disorders, including
bradykinesia, muscle stiffness, resting tremor and imbalance. PD
is pathologically characterized by slow and gradual degeneration
of dopaminergic neurons in the SN compacta that leads to a
decrease in the level of dopamine in the striatum, tailed nuclei
and the putamen (Lees 2012). The progressive loss of dopamin-
ergic neurons in the basal complexes is the most important
pathological finding in the brain of patients with PD.
Destruction of these neurons results in the reduction of dopa-
mine neurotransmitter in this area. After 50–60% of
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dopaminergic neurons are degraded and dopamine levels in the
striatum decrease by around 80–85%, the symptoms of the dis-
ease appear. The exact molecular mechanism of the degradation
of dopaminergic neurons and the incidence of PD is unclear;
however, studies have shown that oxidative stress and mitochon-
drial dysfunction probably play a key role in the pathogenesis of
PD; the loss of nigrostriatal dopaminergic neurons and the pres-
ence of intracellular cytoplasmic proteins, i.e., Lewy bodies, are
also involved. The cells are located in the nigrostriatal neurons
in the SN pars compacta (SNpc) and are sent to putamen. The
absence of these neurons, which typically contain small amounts
of melanin, leads to depigmentation of SNpc (Lees 2012).
Abnormal mitochondrial function and oxidative stress
Accumulating evidence suggests that in PD, the function of
mitochondrial complex I partially decreases. Approximately
100% of molecular oxygen is consumed by the mitochondria
during cellular respiration, and powerful oxidants, including
hydrogen peroxide and superoxide radicals, are produced as a
by-product. Reactive oxygen species (ROS) production increases
by inhibiting mitochondrial complex I, which can produce toxic
hydroxyl radicals or react with nitric oxide and produce peroxy-
nitrites. These molecules can damage the nucleic acids, proteins
and lipids by reacting with nucleic acids. One of these injuries
can occur in the electron transport chain, which can lead to
mitochondrial damage and the formation of ROS that, in turn,
can increase the inappropriate folding of proteins (Gaki and
Papavassiliou 2014).
Much research has also suggested that ROS plays a role in the
degeneration of dopaminergic neurons in the brain tissues of PD
patients (Figure 1). High levels of lipid peroxidation, glutathione
depletion and increase in protein oxidation are observed in the
brain tissues of PD patients. Oxidation of dopamine leads to the
formation of dopamine quinone that can directly alter proteins.
In healthy people, there are mechanisms that prevent the cells
from inappropriate folding and accumulation. For example, these
proteins are harvested by lysosomal and ubiquitin-proteasome
system, as well as certain chaperones can correct these foldings.
It has been suggested that defective mitochondrial function
causes the death of dopaminergic neurons at advanced ages.
Oxidation of RNA and DNA of membrane proteins and lipids is
one of the important factors for defective mitochondrial func-
tion. Oxidation changes the structure of many enzymes and
thereby reduces their tendency to substrates or coenzymes, and
thus their activity (Hwang 2013).
So far, many studies have been done on PD and the effects of
various factors on the symptoms of the disease, the rate of its
progression, and its treatment. Different methods have been used
to induce PD in animal models and then the effects of various
factors on the improvement of its symptoms have been eval-
uated. Animal models greatly help investigate pathogenic mecha-
nisms and design therapeutic strategies in human diseases. Given
that the pathogenesis of PD has not yet been well understood, it
is important to use animal models to better understand the cause
of PD and design the approaches to treat it. To induce PD in
laboratory animals, certain compounds such as reserpine, meth-
amphetamine, 6-hydroxydopamine, paraquat, maneb, rotenone
and 3-nitrotyrosine also transgenic mice are used (Xu
et al. 2002).
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Figure 1. Factors that contribute to oxidative stress and ultimately neuronal cell death in PD.
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The most important approach to treat this disease is the use
of precursors and other analogues of dopamine. There is a limi-
tation in prescribing levodopa. Its chronic use is frequently asso-
ciated with long-term motor impairment and decreased efficacy,
requiring the increased dose of levodopa to reduce the complica-
tions of the disease. The function of levodopa depends on its
enzymatic conversion to dopamine. Therefore, levodopa is usu-
ally prescribed in combination with carbidopa to be converted to
dopamine by the DOPA decarboxylase (Antonini et al. 2010).
The general tendency to use herbal drugs and, in general, nat-
ural products in the world can be due to the side effects of
chemical drugs on the one hand and environmental pollution on
the other hand. Due to increasing prevalence of the nervous sys-
tem disorders (Hasanpour-Dehkordi and Solati 2016;
Hasanpour-Dehkordi et al. 2016; Solati and Lo’Bat Ja’Farzadeh
2016; Solati 2016, 2017) there is a growing tendency to the use
of these plants and the revival of traditional medicine. Recent
research has also reported promising results regarding the effects
of herbal remedies in the treatment or prevention of various dis-
eases, including Alzheimer’s disease (Rabiei et al. 2015; Rabiei
and Setorki 2018), stroke (Rabiei et al. 2012; Rabiei and Rafieian-
Kopaei 2014), depression (Rabiei et al. 2017, 2018) addiction
(Rabiei et al. 2016) and many other conditions. The effects of
medicinal plants and their active ingredients on the treatment of
PD are presented in Tables 1 and 2.
Discussion
Medicinal plants have been discovered by different nations
across the world thousands of years ago. These plants are used
in many communities and countries for centuries due to their
safety, efficiency, acceptability and comparably fewer side effects
than chemical drugs (Alok et al. 2013). Medicinal plants have
long been known throughout the world for their unique and
valuable benefits. Research has also shown that these plants
have a special status in the health and well-being of various
communities due to the antioxidant effect of phenolic com-
pounds identified in them, in addition to their economic value.
Therefore, the global approach is to identify new plant species
and their active ingredients. Today, plants play an important
role in the therapeutic approaches and new drugs used for dis-
eases. Therefore, the demand for new oral medicines without
side effects continues. In this study, the therapeutic effects of
medicinal plants and their compounds on the treatment of PD
observed in vivo and in vitro were reviewed. Although most of
the herbal extracts and their active ingredients have been
studied in PD models in vivo, some of them have so far been
investigated only in cell models (Noelker et al. 2005; Chan et al.
2009; Gao et al. 2009).
To date, a large number of medicinal plants and their active
ingredients have been reported to prevent and treat PD. Most
studies have focused on antioxidant (Ahmad M et al. 2005, 2006;
Chaturvedi et al. 2006; Hritcu et al. 2011; Khuwaja et al. 2011;
Ahmad S et al. 2012; Shobana et al. 2012; Mansouri et al. 2013;
Khatri and Juvekar 2015; Wu et al. 2015), anti-inflammatory
(Farbood et al. 2015) and antiapoptotic (Gao et al. 2009;
Morroni et al. 2013; Kim et al. 2014) properties of these plants.
A number of studies have demonstrated the protective effects
of tea polyphenols on brain damage in different animal models
of PD. Studies have used either a single compound such as
EGCG, or a combination of extracts from tea. Individual EGCG
and black tea polyphenol extracts were observed to mitigate stri-
atal dopamine depletion and SN dopaminergic neurons loss after
being administered for the long term to rats or mice receiving
the parkinsonism-inducing neurotoxins, e.g., 6-OHDA and
1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) (Chaturvedi
et al. 2006).
The aqueous extract of Albizia adianthifolia W. Wight
(Leguminosae) leaves has antioxidant potential and can help
manage neurological abnormalities due to PD. The HPLC ana-
lysis showed that apigenin is the main compound among fla-
vones, and therefore the cause of the cognitive-enhancing
impacts in the 6-OHDA-lesion rodent model of PD. Apigenin
and similar compounds stimulate neurogenesis in adults both in
vivo and in vitro via promoting neuronal differentiation, and
also promote learning and memory according to Morris water
task (Beppe et al. 2014).
At present, the pathogenesis of PD is attributed to the forma-
tion of ROS and the onset of oxidative stress, leading to damage
to the SN compacta, particularly changes in the brain’s iron con-
tent, mitochondrial dysfunction, changes in antioxidant defence
system (especially reduction in superoxide dismutase and gluta-
thione [GSH]) and oxidative damage to fats, proteins and DNA.
The loss of GSH is related to Lewy body disease (Figure 1). GSH
may be the most important biochemical marker for loss of nigral
cells. The depletion of GSH may not be the only reason for dam-
age to nigral neurons, but may increase the susceptibility to
exposure to toxic or free radicals (Hwang 2013). Most of the
medicinal plants and active ingredients reported in this paper
increase the levels of glutathione, superoxide dismutase and cata-
lase in the brain, and thus exert neuroprotective effects. Evidence
indicates the role of inflammation in the pathogenesis of PD.
In patients with PD, the active microglia increase in the stri-
atum and the SN. Microglial cells, which are macrophages in
the brain, respond under numerous unfavourable conditions
through fast hypertrophic proliferation and expression of a
number of cytokines. Active microglia upregulate cell surface
markers, such as macrophage antigen complex 1, produce a
variety of pro-inflammatory cytokines. A number of cytokines,
including IL-1, IL-6 and TNF-a, contribute to the inflamma-
tion process (Niranjan 2014).
Certain active ingredients of plants, such as ellagic acid,
reduce rotation in rats with 6-OHDA-induced PD due to
reduced inflammation by lowering the levels of IL-1b and TNF-
a in the brain tissue (Farbood et al. 2015). Since a plant extract
contains a wide range of compounds, the effects of synergistic
reaction of two or more compounds is higher than those of a
single substance (Williamson 2001). Synergistic effects may be
responsible for the therapeutic effects of many plant-based prod-
ucts. Therefore, herbal extracts can be used to treat PD due to
various bioactive ingredients (Wang et al. 2008).
Conclusions
We sought to present a summary of current experimental evi-
dence on anti-Parkinsonian activities of medicinal plants and
their active ingredients. We found that different natural com-
pounds and herbal extracts exhibit various anti-Parkinsonian
activities. Taken together, various PD neurotoxic models are a
good basis for discovering anti-Parkinsonian drugs, and herbal
drugs can be used to develop new drugs for PD. However, the
efficacy of plant extracts and their active ingredients in PD mod-
els should be further investigated in future empirical studies. In
addition, the active ingredients and action mechanisms of herbal
extracts remain to be adequately explained.
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